Baidu
map

药械

订阅

MedSci主页 / 所有栏目 / 药械

Leukemia：选择性Bcl-2抑制剂ABT-199临床试验证明对白血病疗效良好

2013-12-12 新华网 新华网

ABT-199BCL-2白血病
关注

澳大利亚研究者日前表示，他们对一种白血病新药的试验显示出较好的初步效果，有20%的患者血液中已检测不到癌细胞，这种新药有可能为白血病患者带来治愈希望。 据当地媒体报道，慢性淋巴细胞性白血病是澳大利亚最常见的白血病类型，对这种病一直缺乏有效的治疗方法。澳大利亚“沃尔特与伊丽莎·霍尔医学研究所”经数年研究开发出了这种代号为ABT-199的新药，目前正在墨尔本两家医院对数十名患者进行临床试验。

澳大利亚研究者日前表示，他们对一种白血病新药的试验显示出较好的初步效果，有20%的患者血液中已检测不到癌细胞，这种新药有可能为白血病患者带来治愈希望。

据当地媒体报道，慢性淋巴细胞性白血病是澳大利亚最常见的白血病类型，对这种病一直缺乏有效的治疗方法。澳大利亚“沃尔特与伊丽莎·霍尔医学研究所”经数年研究开发出了这种代号为ABT-199的新药，目前正在墨尔本两家医院对数十名患者进行临床试验。

研究人员康宁·塔姆博士说，经过一年半的试验，有20%的患者血液中已检测不到癌细胞。他说，之前很多患者对化疗和其他治疗方法没有任何积极反应，只能任病情恶化，而“新药完全改变了这一现状”，患者有望恢复健康重回正常生活。

塔姆博士表示，这种药物上市销售还需几年时间，但对愿意参与试验的患者，研究者现在即可提供这种药物。

原始出处：

Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ, Maïga S, Béné MC, Moreau P, Pellat-Deceunynck C, Amiot M.The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma.Leukemia. 2013 Jul 17. doi: 10.1038/leu.2013.216.

Choo EF, Boggs J, Zhu C, Lubach JW, Catron ND, Jenkins G, Souers A, Voorman R.The Role of Lymphatic Transport on the Systemic Bioavailability of the Bcl-2 Protein Family Inhibitors Navitoclax (ABT-263) and ABT-199.Drug Metab Dispos. 2013 Nov 8.

Deng J, Letai A.Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer.Breast Cancer Res. 2013 Oct 31;15(5):317.

Scarfò L, Ghia P.Reprogramming cell death: BCL2 family inhibition in hematological malignancies.Immunol Lett. 2013 Sep-Oct;155(1-2):36-9

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1922848, encodeId=3fa519228489a, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Mon Jan 06 03:32:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707311, encodeId=66e61e073118d, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Mon Aug 11 12:32:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851146, encodeId=d56f18511468e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Sep 24 19:32:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995464, encodeId=a89819954648f, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 15 14:32:00 CST 2014, time=2014-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634978, encodeId=4fdc16349e8d3, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Sat Nov 15 21:32:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981780, encodeId=61cb1981e80d5, content=<a href='/topic/show?id=2b111e82a2' target=_blank style='color:#2F92EE;'>#ABT-199#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1782, encryptionId=2b111e82a2, topicName=ABT-199)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Aug 15 02:32:00 CST 2014, time=2014-08-15, status=1, ipAttribution=)]
    2014-01-06 肉我只吃一口

    #选择性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1922848, encodeId=3fa519228489a, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Mon Jan 06 03:32:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707311, encodeId=66e61e073118d, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Mon Aug 11 12:32:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851146, encodeId=d56f18511468e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Sep 24 19:32:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995464, encodeId=a89819954648f, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 15 14:32:00 CST 2014, time=2014-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634978, encodeId=4fdc16349e8d3, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Sat Nov 15 21:32:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981780, encodeId=61cb1981e80d5, content=<a href='/topic/show?id=2b111e82a2' target=_blank style='color:#2F92EE;'>#ABT-199#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1782, encryptionId=2b111e82a2, topicName=ABT-199)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Aug 15 02:32:00 CST 2014, time=2014-08-15, status=1, ipAttribution=)]
    2014-08-11 ms3323097325231039

    #BCL-2#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1922848, encodeId=3fa519228489a, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Mon Jan 06 03:32:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707311, encodeId=66e61e073118d, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Mon Aug 11 12:32:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851146, encodeId=d56f18511468e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Sep 24 19:32:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995464, encodeId=a89819954648f, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 15 14:32:00 CST 2014, time=2014-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634978, encodeId=4fdc16349e8d3, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Sat Nov 15 21:32:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981780, encodeId=61cb1981e80d5, content=<a href='/topic/show?id=2b111e82a2' target=_blank style='color:#2F92EE;'>#ABT-199#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1782, encryptionId=2b111e82a2, topicName=ABT-199)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Aug 15 02:32:00 CST 2014, time=2014-08-15, status=1, ipAttribution=)]
    2014-09-24 jklm09

    #抑制剂#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1922848, encodeId=3fa519228489a, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Mon Jan 06 03:32:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707311, encodeId=66e61e073118d, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Mon Aug 11 12:32:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851146, encodeId=d56f18511468e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Sep 24 19:32:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995464, encodeId=a89819954648f, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 15 14:32:00 CST 2014, time=2014-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634978, encodeId=4fdc16349e8d3, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Sat Nov 15 21:32:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981780, encodeId=61cb1981e80d5, content=<a href='/topic/show?id=2b111e82a2' target=_blank style='color:#2F92EE;'>#ABT-199#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1782, encryptionId=2b111e82a2, topicName=ABT-199)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Aug 15 02:32:00 CST 2014, time=2014-08-15, status=1, ipAttribution=)]
    2014-09-15 仁医06

    #2抑制剂#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1922848, encodeId=3fa519228489a, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Mon Jan 06 03:32:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707311, encodeId=66e61e073118d, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Mon Aug 11 12:32:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851146, encodeId=d56f18511468e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Sep 24 19:32:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995464, encodeId=a89819954648f, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 15 14:32:00 CST 2014, time=2014-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634978, encodeId=4fdc16349e8d3, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Sat Nov 15 21:32:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981780, encodeId=61cb1981e80d5, content=<a href='/topic/show?id=2b111e82a2' target=_blank style='color:#2F92EE;'>#ABT-199#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1782, encryptionId=2b111e82a2, topicName=ABT-199)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Aug 15 02:32:00 CST 2014, time=2014-08-15, status=1, ipAttribution=)]
    2014-11-15 ms3153534357578991

    #BCL-2抑制剂#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1922848, encodeId=3fa519228489a, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Mon Jan 06 03:32:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707311, encodeId=66e61e073118d, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Mon Aug 11 12:32:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851146, encodeId=d56f18511468e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Sep 24 19:32:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995464, encodeId=a89819954648f, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Sep 15 14:32:00 CST 2014, time=2014-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634978, encodeId=4fdc16349e8d3, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Sat Nov 15 21:32:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981780, encodeId=61cb1981e80d5, content=<a href='/topic/show?id=2b111e82a2' target=_blank style='color:#2F92EE;'>#ABT-199#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1782, encryptionId=2b111e82a2, topicName=ABT-199)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Aug 15 02:32:00 CST 2014, time=2014-08-15, status=1, ipAttribution=)]
    2014-08-15 zhishijing

    #ABT-199#

    0

Baidu
map
Baidu
map
Baidu
map